CureVac (CVAC) announced the appointment of Axel Sven Malkomes as CFO, effective November 11, 2024. Malkomes most recently served as CFO at Cardior Pharmaceuticals GmbH, a private clinical-stage biopharmaceutical company pioneering the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC: